Selank for anxiety and cognition: what the science actually shows

What did @christinemayhemm actually say?

The creator described Selank as a peptide that will "calm you down," help with sleep, lift low mood, act as a "mood booster," and help people who are depressed. The boldest claim: "it has been proven in studies that they can actually help you get off those drugs" — referring to addiction. She also called it an anti-inflammatory and neuromodulator, and recommended stacking it with Semax.

A few things stand out immediately. She consistently mispronounces the peptide as "Selenck," which is minor, but the framing throughout is prescriptive. Phrases like "this is the peptide that you should be taking" and "she is the one" position Selank as a solution for serious mental health conditions. That kind of language, applied to an unregulated research peptide with a limited human trial record, deserves scrutiny.

Does the science back this up?

Some of it, yes — but mostly in ways that are far more cautious than the video implies. Selank is a synthetic heptapeptide derived from tuftsin, developed in Russia by the Institute of Molecular Genetics. It does have documented anxiolytic effects, and the anti-inflammatory and neuromodulatory descriptions are legitimate.

The anxiety evidence is the strongest. Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) found Selank produced anxiolytic effects comparable to benzodiazepines in animal models without sedation. A small Russian clinical trial showed reduced anxiety in generalized anxiety disorder patients. The mechanism appears to involve modulation of GABA-A receptors and influence on BDNF expression, which would support mood-related effects.

The addiction claim is where things get thin. There is preclinical rodent data suggesting Selank reduces alcohol preference and opiate withdrawal symptoms, but calling this "proven in studies" overstates a body of work that has not been replicated in rigorous human trials. The sleep claim has almost no direct human evidence. Most of what exists is animal data or small, non-blinded Russian studies that haven't been independently replicated in Western peer-reviewed journals.

What did they get wrong (or right)?

Credit where it's due: calling Selank an anxiolytic, anti-inflammatory, and neuromodulator is broadly accurate based on available preclinical and limited clinical data. The comparison to Semax as a "sister" peptide is a reasonable lay description — both are synthetic peptides developed in Russia with nootropic and neuroprotective properties, though their mechanisms differ meaningfully.

What's wrong is the certainty. Saying Selank "will" calm you down, "will" help you sleep, and that addiction benefits are "proven" collapses the distance between early-stage research and clinical fact. It also skips entirely over the regulatory reality: Selank is not FDA-approved for any condition. It is not a licensed drug in the United States. The evidence base is dominated by Russian studies, many of which lack the methodology transparency expected in modern clinical research.

The recommendation to stack Selank with Semax without any mention of individual variation, contraindications, or the need for medical oversight is also irresponsible. These are not supplements you buy at a pharmacy. Recommending a specific peptide stack to a general TikTok audience without qualification is the kind of advice that belongs in a clinical conversation, not a 60-second video.

What should you actually know?

Selank is a genuinely interesting compound with a plausible mechanism and some supporting data, particularly for anxiety. But "interesting research compound" and "peptide you should be taking" are very different categories. Anyone considering Selank should understand a few things clearly.

First, the human trial data is sparse and largely from one country. That doesn't make it useless, but it does mean you're working with incomplete information. Second, as a research peptide in the US, Selank exists in a regulatory gray area. Quality, purity, and dosing consistency vary significantly by source. Third, using peptides to self-treat depression, addiction, or sleep disorders without professional involvement can delay access to treatments with far stronger evidence bases.

• Selank has the best evidence for anxiety reduction, based on limited but consistent preclinical and small clinical data.
• Depression and sleep claims have almost no direct human trial support.
• The addiction claim, while not invented, is based on animal studies and should not be described as "proven."
• No peptide on the current research market should be framed as a replacement for addiction treatment without medical supervision.